Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX1100 in Normal Healthy Volunteers and Late-onset Pompe Disease Patients
NCT06109948Phase 1Completed
- Sponsor
- Aro Biotherapeutics
- Start
- Oct 2023
- Primary completion
- Feb 2026
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ABX1100 in Pompe disease (5 arms), sponsored by Aro Biotherapeutics. Primary endpoint: Treatment-Emergent Adverse Events up to 20 weeks. Started Oct 2023; status: completed.
02
Drugs
ABX1100
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT06109948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109948.